Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

HSV-TK-transduced donor lymphocytes

A preparation of donor lymphocytes transduced with the "suicide" gene herpes simplex virus thymidine kinase (HSV-TK) with potential immunomodulating activity. Administration of HSV-TK-transduced lymphocytes after T cell-depleted allogeneic stem cell transplantation allows an early controllable immune reconstitution, which takes advantage of the antitumor effect of donor lymphocytes and helps to mitigate the risk of post-transplant opportunistic infection. To control graft-versus-host disease (GvHD) due to donor lymphocyte infusion, HSV-TK-transduced donor lymphocytes are selectively eliminated by administration of the antiviral agent ganciclovir. Ganciclovir, a prodrug, is readily phosphorylated by the suicide gene HSV-TK within HSV-TK-transduced lymphocytes to its monophosphate form and, subsequently, converted into its active triphosphate form, which specifically kills HSV-TK- transduced donor lymphocytes.
Synonym:HSV-TK-engineered donor lymphocytes
Search NCI's Drug Dictionary